The European Biotech Act 2026: What the New EU Biotechnology Framework Means for Pharma, Biotech and Regulatory Affairs Careers

2 hours ago
12 min read

The **European Biotech Act** is a European Commission legislative proposal, published as **COM(2025) 1022 final on 16 December 2025**, designed to close the EU's competitiveness gap in health biotechnology against the US and China. It affects pharmaceutical companies, biotech start-ups, investors and regulatory affairs professionals working with **ATMPs**, mRNA therapeutics, biologics and biosimilars. The Act introduces faster clinical trial timelines, EU-anchored investment instruments, extended patent protection, regulatory sandboxes and AI integration. It is currently under review by the European Parliament and Council, with agreement unlikely before late 2026 — but its practical measures, including a fast-track clinical trials pilot, are already being rolled out.

European Biotech Act 2026 — overview of the EU's new health biotechnology regulatory framework

1. At a Glance

2. Background: Why the European Biotech Act Was Needed

3. The Seven Key Pillars of the European Biotech Act

4. Biosimilars: A Specific Focus Area

5. A Note of Caution: Demand-Side Challenges Remain

6. Deepen Your Knowledge: Regulatory Affairs Training on This Topic

7. Practical Implications for Regulatory Affairs Professionals

8. Key Takeaways

9. Frequently Asked Questions

10. Further Reading and Sources

At a Glance

- The **European Biotech Act** — formally **Proposal COM(2025) 1022 final** — was published by the European Commission on **16 December 2025**.

- The EU currently attracts only around **7% of global venture capital** in health biotechnology, compared with roughly **63%** for the United States.

- The Act is built around **seven pillars**, including a **Strategic Projects Framework**, an **EU Health Biotechnology Investment Pilot** with the **European Investment Bank (EIB)**, and new **regulatory sandboxes**.

- A proposed **12-month Supplementary Protection Certificate (SPC)** extension could give qualifying biotech products up to six years of protection post-authorisation.

- The Act signals EMA guidance to **reduce clinical data requirements** for **biosimilar** authorisation.

- The Commission's related **Directive proposal COM(2025) 1031 final** covers genetically modified micro-organisms, published the same day.

- A **RAND Corporation** analysis (February 2026) cautions that faster approvals will not automatically improve patient access without demand-side reform.

Background: Why the EU's Biotechnology Competitiveness Gap Demanded Reform

Europe's biotechnology sector faces a genuine structural problem, not a perception issue. Despite hosting world-class research institutions, Nobel Prize-winning science and long-established regulatory systems, the **European Union** has been steadily losing biotechnology investment, clinical trial activity and commercial translation capacity to the **United States** and China. The scale of the gap is significant: independent analysis cited around the Act's publication put EU biotech venture capital at roughly **€25 billion between 2015 and mid-2025**, against approximately **€219 billion** raised by US biotech companies over a comparable period. The EU and EEA's share of global commercial clinical trials has also declined — from around 22% a decade ago to roughly 12% by 2024. These are not marginal shifts; they represent a widening divide between where biotechnology is discovered and where it is commercialised.

The European Commission's response has been developing for some time. **Commission President Ursula von der Leyen** first flagged a Biotech Act in her **2024–2029 political priorities**, framing it as part of the broader effort to close the EU's "innovation gap." On **16 December 2025**, the Commission formally published its **Proposal for a Regulation establishing measures to strengthen the Union's biotechnology and biomanufacturing sectors** — **COM(2025) 1022 final** — alongside a companion **Proposal for a Directive on the placing on the market of genetically modified micro-organisms**, **COM(2025) 1031 final**. Both proposals sit within the Commission's wider **EU Life Sciences Strategy for 2024–2029** and accompany the agreed **EU Pharma Package**. The Commission has signalled that a second, broader **Biotech Act** covering industrial biotechnology and biomanufacturing beyond health is expected later in 2026.

Interested in building a career in regulatory affairs and working with frameworks like the European Biotech Act, ATMP regulation and EU biosimilar pathways? The **Comprehensive Regulatory Affairs Course** at Entry to Regulatory covers EU marketing authorisation procedures, ATMP and cell and gene therapy regulation, clinical trials strategy, and the practical skills regulatory teams need as EU biotechnology legislation evolves. - 50+ CPD-accredited hours of expert-led training - Up to 3 months of real regulatory work experience - Mentoring and job search support until you are employed - Covers EU, UK and US pharmaceutical regulations - Taught by a regulatory affairs expert with 10+ years at MHRA, GSK, MSD and Bayer - Study online, part-time, just 6 hours per week View the course

The causes of the EU's competitiveness gap are well documented and interconnected: fragmented national regulatory requirements, lengthy clinical trial authorisation timelines, insufficient risk capital for deep biotech research and development, limited manufacturing scale-up infrastructure, and regulatory complexity around novel products — particularly **Advanced Therapy Medicinal Products (ATMPs)** — that sit across multiple overlapping legal frameworks including the medicines and medical devices regimes. Rather than a single fix, the European Biotech Act attempts to address each of these bottlenecks through a coordinated set of legislative and operational instruments, which is why it has been described as one of the most sweeping life sciences regulatory overhauls in recent EU history. Understanding how these instruments fit together, and how they interact with existing EU and UK regulatory pathways, is a core component of the Entry to Regulatory regulatory affairs training programme, which covers EU marketing authorisation and lifecycle regulatory strategy as part of its practical curriculum for EU, UK and US regulations — see the full course details at https://pages.entrytoregulatory.com/courses/

EU biotechnology investment gap — comparison of venture capital flows between the EU and United States

The Seven Key Pillars of the European Biotech Act

The Act is structured around seven interlocking pillars, each targeting a specific bottleneck identified by the Commission's supporting impact assessment.

1. **Strategic Projects Framework.** The Act introduces two new designations — **Health Biotechnology Strategic Projects** and **High Impact Health Biotechnology Strategic Projects** — for products making a substantial contribution to stated EU health priorities or carrying strong cross-border relevance. Designated products gain expedited regulatory and administrative review, priority access to EU funding streams, and support through testing environments and biomanufacturing training centres. An **EU Health Biotechnology Support Network** of national and regional bodies is also proposed to help smaller developers, particularly SMEs, navigate regulatory pathways.

2. **EU Health Biotechnology Investment Pilot.** Established in partnership with the **European Investment Bank (EIB) Group** and initially funded for two years, this pilot combines equity instruments and venture-style debt aimed specifically at the biotech risk profile — addressing the well-documented gap in patient capital that has pushed many early-stage EU biotech companies to seek funding, and sometimes list, abroad.

3. **Supplementary Protection Certificate (SPC) extension.** The Act proposes a **12-month extension** to SPCs for qualifying biotech-derived medicinal products and ATMPs, potentially extending effective protection from five to six years post-authorisation. Eligibility requires: a new active substance distinct from any already-authorised product; a distinctly different mechanism of action with at least equivalent safety and efficacy; clinical trials conducted in more than two EU member states; and at least one manufacturing step (excluding packaging, testing and certification) performed within the EU.

4. **Streamlined clinical trial authorisation.** Amendments to the **Clinical Trials Regulation (EU) No 536/2014** aim to compress authorisation timelines across all product types, not only biotech. A **FAST-EU pilot programme** has already been operationalised ahead of the Act's formal adoption, with EFPIA and Vaccines Europe noting the ambition to bring clinical trial approval timelines down to around 75 days.

5. **Regulatory sandboxes.** Controlled environments allow novel or atypical products — including combination products, novel cell and gene therapy approaches, AI-supported trial designs, and **New Approach Methodologies (NAMs)** as alternatives to traditional preclinical animal models — to be tested under regulatory supervision without being forced into an unsuitable existing framework. A single authorisation pathway is also proposed for combined medicinal product/medical device and in vitro diagnostic (IVD) trials.

6. **AI, data and the European Health Data Space.** The Act promotes AI and data technologies throughout the biotechnology development lifecycle, including integration with the **European Health Data Space**, trusted AI testing environments, and data-quality accelerators. The **European Data Protection Board (EDPB)** and **European Data Protection Supervisor (EDPS)** issued a joint supportive opinion in early 2026 on harmonising personal data processing in clinical trials while maintaining **GDPR** compliance.

7. **Biosecurity and biodefence.** Harmonised EU-wide biosecurity rules — a framework that did not previously exist at EU level — cover prevention of biotechnology misuse, enhanced oversight of high-risk biological materials, and coordination mechanisms for biodefence strategy. A parallel proposal introduces a streamlined authorisation framework for genetically modified micro-organisms (GMMs), including a new "low-risk GMM" category, via **COM(2025) 1031 final**.

Regulatory professionals looking to deepen their understanding of ATMP classification, clinical trials strategy and the EU regulatory sandbox concept will find relevant practical training in the Entry to Regulatory course, which includes hands-on assignments covering EU regulatory pathways and lifecycle management as part of its EU/UK regulatory curriculum. Full details at https://pages.entrytoregulatory.com/courses/

The seven pillars of the European Biotech Act — regulatory sandboxes, SPC extension and EU investment pilot

Biosimilars: A Specific Focus Area

The Act signals a clear policy direction for **biosimilar medicines**, urging the **European Medicines Agency (EMA)** to develop new guidelines that facilitate biosimilar authorisation, including a reduction of the clinical data required for approval. This direction follows the **AUGMENT study**, an EU-funded project assessing barriers to biosimilar uptake across member states, whose findings were referenced in late 2025 discussions around the Act. Note: the precise publication date and full findings of the AUGMENT study could not be independently verified against a second named source at the time of writing and should be checked against EMA's own biosimilar guidance pages before being cited in a regulatory submission context. The Commission's dual focus on easing biosimilar development and encouraging uptake represents a meaningful commercial and regulatory opportunity for companies and regulatory teams working in this space, particularly as complex biologics come off patent across multiple regions simultaneously.

A Note of Caution: Demand-Side Challenges Remain

A **RAND Corporation** analysis published in **February 2026** raises an important counterpoint that regulatory and market access professionals should not overlook: while the European Biotech Act addresses supply-side barriers effectively, demand-side conditions for biotech medicines across EU member states remain inconsistent. **Health Technology Assessment (HTA)** fragmentation, varying reimbursement timelines, and differing pricing pressures persist between member states. Without stronger demand-side coordination — including clearer pathways from authorisation to reimbursement — faster regulatory approval may not automatically translate into improved patient access or commercial returns. EFPIA and Vaccines Europe echoed a related concern in their public statements, welcoming the Act's clinical trial and investment measures while flagging that intellectual property incentives may be limited to a narrow subset of products. For regulatory and market access professionals, understanding both sides of this equation — the regulatory pathway and the reimbursement pathway — is increasingly essential to advising development strategy accurately.

Deepen Your Knowledge: Regulatory Affairs Training on This Topic

Working with a legislative framework as multi-layered as the European Biotech Act requires regulatory affairs professionals to move fluidly between EU marketing authorisation procedures, ATMP and biosimilar classification, clinical trials regulation, and an understanding of how EU frameworks differ from UK MHRA and US FDA requirements post-Brexit. This is not knowledge that develops from reading policy summaries alone — it requires structured exposure to how these frameworks are applied in practice, including how strategic project designations, SPC eligibility criteria and regulatory sandbox applications are actually assembled and submitted.

The Entry to Regulatory course curriculum directly addresses these areas. Its EU-focused modules cover marketing authorisation submissions, variations, and the practical mechanics of the EU centralised, mutual recognition and decentralised procedures that are directly referenced throughout the Biotech Act's document reuse and strategic project provisions. For professionals working closer to product development, the course's CMC and biologics-related content builds the technical grounding needed to assess SPC eligibility and biosimilar data requirements accurately.

This training is most valuable for life science graduates seeking entry-level regulatory roles, scientists and CMC/QA professionals transitioning into regulatory affairs, pharmacy professionals moving out of dispensing roles, and existing regulatory affairs professionals who need to build EU biotech-specific fluency ahead of the Act's implementation.

**TRAINING SPOTLIGHT BOX:** Course: Comprehensive Regulatory Affairs Course Provider: Entry to Regulatory Relevant to this topic: EU marketing authorisation procedures, ATMP and cell/gene therapy regulatory classification, clinical trials regulation, biosimilar development strategy, CMC for biologics Format: Online, part-time | 6 hours per week | 3 months Includes: Up to 3 months real work experience, job mentoring, CV review, mock interviews, industry-recognised certificate Suitable for: Life science graduates, pharmacy professionals, career changers, scientists seeking regulatory transition Start here

Practical Implications for Regulatory Affairs Professionals

The European Biotech Act changes the practical questions regulatory teams and sponsors need to be asking right now. The table below sets out common questions and how the position is shifting.

Key Question	Previous Situation	What Changes Now
Does our ATMP pipeline qualify for expedited review?	No dedicated fast-track designation existed for cross-border health biotech products	Strategic Project and High Impact Strategic Project designations offer expedited review and funding access for qualifying products
Can we extend patent protection on a novel biologic?	SPC protection was capped without a biotech-specific extension route	A proposed 12-month SPC extension is available if the product meets all four eligibility conditions, including an EU manufacturing step
How long will our clinical trial authorisation take?	Timelines varied significantly by member state, often exceeding 75-106 days	The FAST-EU pilot and Clinical Trials Regulation amendments target substantially shorter, more harmonised timelines
What happens if our product doesn't fit an existing regulatory category?	Combination and first-in-class products risked delays from framework mismatch	Regulatory sandboxes allow supervised testing outside the existing rigid framework
Where can early-stage biotech SMEs access risk capital in the EU?	Limited patient capital pushed many start-ups toward US investors or listings	The EU Health Biotechnology Investment Pilot with the EIB offers equity and venture-style debt anchored in the EU
Will faster approval guarantee faster patient access?	Approval and reimbursement were only loosely connected	RAND Corporation analysis confirms demand-side HTA and reimbursement fragmentation remains unresolved, so approval speed alone is not sufficient
Are biosimilar clinical data requirements changing?	Full comparative clinical data packages were generally expected	EMA is being encouraged to develop guidelines reducing biosimilar clinical data requirements

Key Takeaways

1. **Assess strategic project eligibility early.** If your pipeline includes ATMPs, mRNA therapies or high unmet need products, review the designation criteria before they become competitive.

2. **Audit SPC eligibility now.** For biotech products in late-stage development, check all four SPC extension conditions — including the EU manufacturing step — well before submission, not at the point of filing.

3. **Monitor the legislative timetable.** Track European Parliament and Council progress on COM(2025) 1022 final; agreement is unlikely before late 2026, but positions can shift quickly.

4. **Prepare internal processes for faster trial timelines.** Review your internal document preparation and sign-off workflows so they can match compressed authorisation windows once implemented.

5. **Build biosimilar regulatory capability ahead of formal EMA guidance.** Companies that develop this expertise before the simplified guidelines land will have a first-mover advantage.

6. **Bridge regulatory and market access skills.** Given the demand-side gap RAND has identified, build or access market access and HTA literacy alongside regulatory expertise.

7. **Track the second Biotech Act.** The industrial biotechnology and biomanufacturing Act expected later in 2026 will carry separate implications for manufacturing and supply chain compliance strategy.

Take the Next Step in Your Regulatory Affairs Career

The European Biotech Act illustrates something regulatory affairs professionals see repeatedly: regulatory frameworks evolve constantly, and the ability to understand and apply a new framework quickly is one of the most valuable skills in this profession, whatever level you are working at. Whether you are trying to enter regulatory affairs for the first time or looking to build EU biotech-specific expertise on top of existing experience, structured, practical training makes the difference between reading about a regulatory shift and being ready to work within it.

Entry to Regulatory offers a genuinely low-commitment way to explore whether this is the right path for you — starting with a free introductory webinar, with no obligation to enrol in a full course afterwards.

Explore the full course details and register for a free introductory webinar at Entry to Regulatory: https://pages.entrytoregulatory.com/courses/

Regulatory affairs professional studying EU biotech regulation online — pharmaceutical industry career development

Frequently Asked Questions

What is the European Biotech Act?

The European Biotech Act is a legislative proposal published by the European Commission as **COM(2025) 1022 final** on **16 December 2025**. It aims to strengthen the EU's competitiveness in health biotechnology by simplifying regulatory pathways, improving funding access, extending intellectual property protection for certain products, and promoting AI and data use in biotech development.

When will the European Biotech Act come into force?

The Act is currently in the legislative process, under review by the European Parliament and Council. An agreement is unlikely before the end of 2026. The FAST-EU pilot and some operational measures are already being implemented ahead of formal adoption.

What medicines are affected by the Biotech Act?

The Act primarily targets health biotechnology, including ATMPs (gene and cell therapies), mRNA products, biologics and biosimilars. Some amendments, particularly to the Clinical Trials Regulation, apply to all medicines regardless of modality.

How does the Biotech Act affect biosimilars?

The Act encourages EMA to develop new guidelines that reduce the clinical data requirements for biosimilar authorisation, potentially lowering development costs and timelines and supporting broader market uptake.

How can I build a career in regulatory affairs around EU biotech legislation like this?

Regulatory affairs roles increasingly require practical understanding of frameworks like the European Biotech Act, not just theoretical awareness. The Entry to Regulatory course provides structured, hands-on training in EU marketing authorisation, ATMP and biologics regulation, alongside job search support, making it a practical route into or within this specialism — details at https://pages.entrytoregulatory.com/courses/

Speak To Us